All articles tagged with #nodthera
NodThera, a decade-old developer of NLRP3 inflammasome inhibitors, plans Phase 3 trials in 2027 and is undergoing a brand overhaul to Rezera, signaling a strategic pivot for its anti-inflammatory program.
NodThera is advancing its NLRP3 inhibitors into clinical trials after preclinical data demonstrated their potential to reverse obesity and inflammation in mice, with its lead candidate, NT-0796, resulting in a 19% weight loss in mice over 28 days, comparable to the weight loss seen with Novo Nordisk’s Wegovy.